Amarantus BioSciences President & CEO Gerald Commissiong, talks live with ‘The Stock Radio’ from Wall Street 1-2-1 event in Orlando, Florida

SUNNYVALE, Calif., May 30, 2012 /PRNewswire/ – Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including Parkinson’s disease and traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic… View full post on PR Newswire: Internet Technology

Leave a Reply

Your email address will not be published. Required fields are marked *